Gene: PARN

5073
DAN|DKCB6|PFBMFT4
poly(A)-specific ribonuclease
protein-coding
16p13.12
Ensembl:ENSG00000140694 MIM:604212 Vega:OTTHUMG00000173199 UniprotKB:O95453
NG_042871.1
PubMed|SNP Mapped
2   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.739e-1 (AD)  5.332e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12446921chr16:14535631 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs732459chr16:14533837 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg27550441chr16:14530550PARN9.500e-9Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
VPS33B0.934
GLE10.922
GSTA40.922
FAF10.918
DCAF80.917
GSS0.915
WDR700.913
EXOC10.913
MRPS270.911
STRADA0.908

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.577
OR4F29-0.54
MTRNR2L6-0.44
MTRNR2L9-0.438
MTRNR2L10-0.395
TTLL10-0.35
EVC2-0.348
MTRNR2L2-0.347
FOXJ1-0.347
MTRNR2L8-0.346

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C006632arsenic trioxidearsenic trioxide results in increased expression of PARN mRNA25258189
D001280AtrazineAtrazine results in decreased expression of PARN mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PARN mRNA20064835|2010694
C006780bisphenol Abisphenol A affects the expression of PARN mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PARN mRNA28628672
C025703bleomycetinbleomycetin results in increased expression of PARN mRNA21040473
D002084Butylated HydroxytolueneButylated Hydroxytoluene results in decreased expression of PARN mRNA19925653
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PARN gene20938992
D019327Copper SulfateCopper Sulfate results in decreased expression of PARN mRNA19549813
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PARN mRNA28628672
D002945CisplatinCisplatin results in decreased expression of PARN mRNA19561079
D004791Enzyme Inhibitors[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of PARN protein23301498
C000591741Firemaster 550Firemaster 550 results in increased expression of PARN mRNA27957850
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PARN gene20938992
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PARN mRNA28628672
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PARN mRNA25613284
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PARN mRNA28628672
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PARN gene20938992
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of PARN mRNA"20188158
D010416PentachlorophenolPentachlorophenol results in increased expression of PARN mRNA24642059
D011192Potassium DichromatePotassium Dichromate results in decreased expression of PARN protein23718831
D011374ProgesteroneProgesterone results in increased expression of PARN mRNA23012394
C045950propiconazolepropiconazole results in decreased expression of PARN mRNA21278054
C059514resveratrolresveratrol results in decreased expression of PARN protein25505154
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PARN mRNA22298810
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PARN mRNA25613284
D014635Valproic AcidValproic Acid affects the expression of PARN mRNA25979313
D014810Vitamin EVitamin E results in increased expression of PARN mRNA19244175

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:00001753'-5'-exoribonuclease activity-IBA21873635  
GO:0003723RNA binding-HDA22658674  
GO:0003723RNA binding-IBA21873635  
GO:0003730mRNA 3'-UTR binding-TAS9736620  
GO:0004518nuclease activity-TAS9736620  
GO:0004535poly(A)-specific ribonuclease activity-IBA21873635  
GO:0004535poly(A)-specific ribonuclease activity-IDA25049417  
GO:0004535poly(A)-specific ribonuclease activity-IMP26482878  26950371  
GO:0004535poly(A)-specific ribonuclease activity-TAS-  
GO:0005515protein binding-IPI20379136  21876179  
GO:0019901protein kinase binding-IPI20932473  
GO:0043169cation binding-IMP15358788  
GO:0046872metal ion binding-IEA-  
GO:0070034telomerase RNA binding-IC26482878  26950371  
GO ID GO Term Qualifier Evidence PubMed
GO:0000184nuclear-transcribed mRNA catabolic process, nonsense-mediated decay-IEA-  
GO:0000289nuclear-transcribed mRNA poly(A) tail shortening-IBA21873635  
GO:0000289nuclear-transcribed mRNA poly(A) tail shortening-TAS-  
GO:0000495box H/ACA snoRNA 3'-end processing-IDA22442037  
GO:0007292female gamete generation-TAS9736620  
GO:0009451RNA modification-TAS9736620  
GO:0010587miRNA catabolic process-IDA25049417  
GO:0032212positive regulation of telomere maintenance via telomerase-IMP26482878  26950371  
GO:0043488regulation of mRNA stability-TAS-  
GO:0051973positive regulation of telomerase activity-IMP26482878  
GO:0071051polyadenylation-dependent snoRNA 3'-end processing-IDA22442037  
GO:0090503RNA phosphodiester bond hydrolysis, exonucleolytic-IMP26482878  
GO:0090669telomerase RNA stabilization-IMP26482878  26950371  
GO:0110008ncRNA deadenylation-IMP26482878  26950371  
GO:1904872regulation of telomerase RNA localization to Cajal body-IMP26950371  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-TAS9736620  
GO:0005730nucleolus-IDA22442037  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-TAS9736620  
GO:0005829cytosol-TAS-  
KEGG ID KEGG Term
hsa03018RNA degradation
Reactome ID Reactome Term Evidence
R-HSA-380994ATF4 activates genesTAS
R-HSA-381042PERK regulates gene expressionTAS
R-HSA-381119Unfolded Protein Response (UPR)TAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-429914Deadenylation-dependent mRNA decayTAS
R-HSA-429947Deadenylation of mRNATAS
R-HSA-450531Regulation of mRNA stability by proteins that bind AU-rich elementsTAS
R-HSA-450604KSRP (KHSRP) binds and destabilizes mRNATAS
R-HSA-8953854Metabolism of RNATAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
20301779Dyskeratosis Congenita (1993)Savage SA-